Learn about our expanded patient care options for your health care needs.
General Information | Self-Checker | Donate and Lend Support | Staff Appreciation | Get Email Alerts
Enter the last name, specialty or keyword for your search below.
Clinical trials come from the discoveries made in basic science laboratories. By taking these investigations and discoveries, researchers and scientists can create new therapies and treatments. Below are the listings of our current clinical trials.
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
|---|---|---|---|
R1216
| Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck | Ana Kiess
| Amber Michalik |
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
|---|---|---|---|
J1918 | Adjuvant Therapy for High-Risk HPV16-positive Oropharynx Cancer Patients with Durvalumab (MEDI4736) and MEDI0457 (INO-3112) | Carole Fakhry | Bhavika Patel |
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
|---|---|---|---|
J1923 | Preoperative Immune Checkpoint Inhibitor for Patients with Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (RM-SCCHN) Undergoing Surgical Resection (CA209-9H7) | Patrick Forde | Michelle Thomas |
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
|---|---|---|---|
J15183 | A Phase II Trial of Reirradiation Combined with Open Label MK-3475 (Pembrolizumab) in Patients with Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Ana Kiess | Riley McIntryre |
| J15117 | Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors (CheckMate 358) | William Sharman | Jing Ye |
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
|---|---|---|---|
J1480 | My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents (Protocol Number: ML28897/PRO 02) | Adrain Murphy | Kimberly White |
Detailed descriptions of these trials are available at www.clinicaltrials.gov
Request an Appointment
Traveling for Care?
Whether you're crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.
Outside of Maryland (toll free)
410-464-6713
Request an Appointment
Medical Concierge Services
International Patients
+1-410-502-7683
Request an Appointment
Medical Concierge Services
The Allegheny Health Network collaborates on an array of initiatives that support cancer care and research.. Learn more.
Latest News from the Kimmel Cancer Center
Read Now
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
